Skip to main navigation
Skip to search
Skip to main content
Universidad del Rosario Home
English
Español
Home
Profiles
Research units
Research output
Projects
Press/Media
Datasets
Prizes
Activities
Impacts
Student theses
Search by expertise, name or affiliation
Intravitreal bevacizumab (Avastin®) for diabetic retinopathy at 24-months: The 2008 Juan Verdaguer-planas lecture
urosario
Research output
:
Contribution to journal
›
Article
›
peer-review
26
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Intravitreal bevacizumab (Avastin®) for diabetic retinopathy at 24-months: The 2008 Juan Verdaguer-planas lecture'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Bevacizumab
100%
Diabetic Retinopathy
93%
Macular Edema
64%
Light Coagulation
26%
Vascular Endothelial Growth Factor A
19%
Intravitreal Injections
13%
Retinal Detachment
12%
Retina
9%
Visual Acuity
9%
Permeability
9%
Ocular Vision
9%
Lasers
9%
Ischemia
8%
Growth
5%
Population
4%
Proteins
4%
Therapeutics
3%